HCW Biologics Inc. Common Stock
HCWB XNASAbout HCW Biologics Inc. Common Stock
HCW Biologics Inc is a clinical-stage biopharmaceutical company developing transformative fusion immunotherapeutics to support or treat diseases promoted by chronic inflammation. It has created novel compounds that represent a new class of drugs that it believes has the potential to fundamentally change the treatment of autoimmune disorders and other proinflammatory diseases, cancer and senescence-associated dysplasia. The company has developed two proprietary drug discovery and development platforms which it uses to create novel fusion immunotherapeutics: The TOBI (Tissue factOr-Based fusIon) platform, and The T-cell Receptor Beta Chain constant region (TRBC) platform. It operates and manages its business as one reportable segment.
Key Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $6.50M | $3.47M | $0.37 |
| FY 2025 | $54.2K | $-7,959,709 | $-10.63 |
| Q3 2025 | $15.6K | $-4,554,336 | $-2.02 |
| Q2 2025 | $6.5K | $-1,927,730 | $-6.79 |
TickerDaily Coverage
Get HCWB Alerts
Stay ahead with breaking news, price alerts, and expert analysis on HCW Biologics Inc. Common Stock.